Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.

Science translational medicine - 30 Mar 2011

Lyubynska Natalya, Gorman Matthew F, Lauchle Jennifer O, Hong Wan Xing, Akutagawa Jon K, Shannon Kevin, Braun Benjamin S

Abstract excerpt

Chronic and juvenile myelomonocytic leukemias (CMML and JMML) are aggressive myeloproliferative neoplasms that are incurable with conventional chemotherapy. Mutations that deregulate Ras signaling play a central pathogenic role in both disorders, and Mx1-Cre, Kras(LSL-G12D) mice that express the Kras oncogene develop a fatal disease that closely mimics these two leukemias in humans. Activated Ras controls...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Differentiation
Share to GTP-Binding Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Inbred C57BL

Share to Mutation

Share to Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Recombinant Fusion Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 21451123
DOI: 10.1126/scitranslmed.3001069
PMCID: PMC3265440

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.PMID 21451123Read ↗

Somatic activation of oncogenic <i>Kras</i> in hematopoietic cells initiates a rapidly fatal myeloproliferative disorderSemantic proximity Read ↗

Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110αSemantic proximity Read ↗

Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant miceSemantic proximity Read ↗

Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require ErkSemantic proximity Read ↗

Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.Semantic proximity Read ↗

Targeting RAS Signaling Pathways in Juvenile Myelomonocytic LeukemiaSemantic proximity Read ↗

Oncogenic KrasG12D Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice.Semantic proximity Read ↗

Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.Semantic proximity Read ↗

Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.Semantic proximity Read ↗

Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.Semantic proximity Read ↗

AKT is a therapeutic target in myeloproliferative neoplasms.Semantic proximity Read ↗

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.